SOPHiA GENETICS (SOPH) AI Stock Analysis

• Market Cap: $316.27M
• Dividend Yield: N/A
• Average Volume (3M): 100.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: 13.66%
• EPS Growth: -2.65%
• Country: US
• Employees: 423
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.30
• Shares Outstanding: 67,579,560
• 10 Day Avg. Volume: 137,858
• 30 Day Avg. Volume: 100,949
• PEG Ratio: 0.15
• Price to Book (P/B): 2.10
• Price to Sales (P/S): 3.11
• P/FCF Ratio: -3.98
• Enterprise Value/Market Cap: 0.56
• Enterprise Value/Revenue: 2.42
• Enterprise Value/Gross Profit: 3.59
• Enterprise Value/Ebitda: -3.10
• 1Y Price Target: $7.00
• Price Target Upside: 60.18% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $5.50 ▲(25.86% Upside)

SOPHiA GENETICS' stock score is primarily driven by its strong technical indicators and positive earnings call sentiment, which highlight growth and strategic expansion. However, financial performance and valuation concerns, such as profitability challenges and a negative P/E ratio, weigh down the overall score.

Positive Factors

Revenue Growth

Sustained revenue growth indicates strong market demand and effective customer acquisition strategies, enhancing long-term business viability.

U.S. Market Expansion

Expansion in the U.S. market strengthens SOPHiA GENETICS' competitive position and diversifies its revenue base, supporting future growth.

Innovation and AI Development

Innovative AI tools enhance product offerings, potentially improving diagnostic accuracy and attracting more customers, driving long-term growth.

Negative Factors

Operating Loss and Cash Burn

Persistent operating losses and increased cash burn could strain financial resources, challenging the company's ability to sustain operations.

Profitability Challenges

Continued profitability issues may limit reinvestment in growth initiatives and hinder long-term financial health.

Legal and Currency Challenges

Legal and currency challenges increase operational costs and financial uncertainty, potentially affecting future profitability and strategic plans.

SOPHiA GENETICS Business Overview & Revenue Model

Company Description

SOPHiA GENETICS (SOPH) is a biotechnology company specializing in data-driven medicine and advanced genomic analysis. Founded in 2011 and headquartered in Switzerland, the company operates primarily in the healthcare sector, focusing on the integration of genomic data with clinical data to improve patient outcomes. SOPHiA GENETICS offers a comprehensive platform that includes a suite of software solutions and services for genomic data analysis, primarily targeting oncology, hereditary disorders, and infectious diseases. Its core product, the SOPHiA DDM™ (Data-Driven Medicine) platform, enables healthcare professionals to leverage genomic data for more accurate diagnostics and personalized treatment plans.

How the Company Makes Money

SOPHiA GENETICS generates revenue through several key streams, primarily focusing on software-as-a-service (SaaS) solutions and genomic data analysis services. The company charges fees for access to its SOPHiA DDM™ platform, which includes subscription fees, pay-per-use models, and service contracts with hospitals, laboratories, and research institutions. Additionally, SOPHiA GENETICS collaborates with pharmaceutical companies in companion diagnostics, where they provide genomic analysis services to support drug development and clinical trials, often receiving funding or revenue-sharing agreements in return. Strategic partnerships with healthcare providers and research organizations further enhance its revenue potential by expanding its market reach and driving adoption of its platform in clinical settings.

SOPHiA GENETICS Financial Statement Overview

Summary

SOPHiA GENETICS shows revenue growth and stable gross margins but faces significant profitability and cash flow challenges. The balance sheet indicates manageable leverage, yet negative returns on equity highlight the need for operational improvements.

Income Statement

SOPHiA GENETICS shows a consistent revenue growth trend, with a 5.18% increase in TTM. However, the company struggles with profitability, evidenced by negative net profit margins and EBIT margins. The gross profit margin remains relatively stable, indicating efficient cost management, but the persistent negative net income and EBIT suggest ongoing operational challenges.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.83 in TTM, indicating manageable leverage. However, the return on equity is negative, highlighting profitability issues. The equity ratio suggests a stable capital structure, but the company needs to improve its returns to enhance financial health.

Cash Flow

The cash flow statement reveals negative operating and free cash flows, with a decline in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. Despite a positive free cash flow to net income ratio, the overall cash flow situation requires improvement to support sustainable operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	73.30M	65.17M	62.37M	47.56M	40.45M	28.40M
Gross Profit	49.49M	43.94M	42.91M	31.25M	25.22M	17.69M
EBITDA	-57.36M	-50.76M	-69.57M	-81.38M	-69.24M	-37.99M
Net Income	-74.98M	-62.49M	-78.98M	-87.45M	-73.67M	-39.34M
Balance Sheet
Total Assets	163.46M	155.31M	206.16M	243.84M	320.17M	132.12M
Cash, Cash Equivalents and Short-Term Investments	81.61M	80.23M	123.25M	178.61M	265.32M	97.34M
Total Debt	63.37M	30.03M	18.60M	16.74M	13.06M	7.25M
Total Liabilities	102.77M	58.82M	54.71M	43.71M	44.77M	31.61M
Stockholders Equity	60.69M	96.49M	151.44M	200.13M	275.40M	100.51M
Cash Flow
Free Cash Flow	-43.87M	-51.00M	-57.80M	-80.47M	-64.61M	-34.93M
Operating Cash Flow	-38.36M	-42.82M	-48.58M	-70.09M	-57.94M	-31.73M
Investing Cash Flow	-7.11M	-8.18M	8.32M	41.97M	-56.93M	-24.32M
Financing Cash Flow	29.99M	11.59M	-2.82M	-1.57M	237.77M	107.05M

SOPHiA GENETICS Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.37
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SOPH, the sentiment is Positive. The current price of 4.37 is below the 20-day moving average (MA) of 4.42, above the 50-day MA of 4.02, and above the 200-day MA of 3.47, indicating a neutral trend. The MACD of 0.17 indicates Positive momentum. The RSI at 49.92 is Neutral, neither overbought nor oversold. The STOCH value of 41.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SOPH.

SOPHiA GENETICS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WGS	68 Neutral	$4.01B	2,317.25	0.84%	―	50.50%	―
OMDA	58 Neutral	$1.34B	―	―	―	47.99%	44.25%
SOPH	57 Neutral	$316.27M	-4.26	-86.09%	―	13.66%	-2.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SDGR	48 Neutral	$1.37B	―	-45.67%	―	32.90%	1.85%
DH	48 Neutral	$396.10M	-1.05	-64.27%	―	-5.24%	23.59%
ZCMD	43 Neutral	$18.51M	-3.74	-8.96%	―	-24.64%	92.19%

SOPHiA GENETICS Corporate Events

SOPHiA GENETICS Reports Financial Results for Q3 2025

On November 4, 2025, SOPHiA GENETICS SA released its unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025. The company reported a revenue increase compared to the previous year, but it also experienced a significant loss for the period. This financial update reflects the company’s ongoing investment in research and development, as well as selling and marketing efforts, which are crucial for its growth and competitive positioning in the biotechnology sector.